Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 55

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 55
---
   |      5,867,880 |   |     |   |          5,378,456 |   |
| Working capital     |     | $ |     (5,716,131 | ) |     | $ |         (5,235,105 | ) |

Working capital deficit increased by $ 481,026 from September 30, 2024 to March 31, 2025, primarily due to increase in Derivative Liability.

|                                                      |     | Six Months Ended 
 March 31,        |     2025 |   |     |   |     2024 |   |
|:-----------------------------------------------------|:----|:-----------------|---------:|:--|:----|:--|---------:|:--|
| Net cash used in operating activities                |     | $                | (167,609 | ) |     | $ | (371,658 | ) |
| Net cash provided by financing activities            |     |                  |  168,655 |   |     |   |  328,734 |   |
| Net increase (decrease) in cash and cash equivalents |     | $                |    1,045 |   |     | $ |  (42,934 | ) |
| Cash, beginning of period                            |     |                  |      716 |   |     |   |  121,037 |   |
| Cash, end of period                                  |     | $                |    1,761 |   |     | $ |   78,114 |   |

Liquidity and Capital Resources

Operating Activities

Net cash used in operating activities for the six months ended March 31, 2025 was $167,609, compared to $371,658, for the same period ended 2024, a decrease of $204,049. The decrease in cash used in operating activities is primarily attributable to decreased operating expenses incurred by the Company during the six months ended March 31, 2025 as compared to the same period ended 2024.

Financing Activities

Net cash generated by financing activities for the six months ended March 31,2025 was $168,655 which consisted of proceeds from notes payables.

<div align='center'>40</div>

Liquidity & Capital Resources Outlook

As of December 31, 2024, the Company had cash of $ 1,761 and net working capital of ($5,716,131)

The Company has incurred